Startup profile · funding coverage
Anew Labs funding, valuation and investors
ByteDance-spun AI drug-discovery company — Reuters reported a $290 million inaugural external raise at $1.5 billion; ByteDance and investors did not comment.
Keep track of Anew Labs
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Inaugural external (reported)
$290M · September 2026
Latest known valuation
$1.5B
Inaugural external (reported) · September 2026
Total disclosed equity funding
$290M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
Stage not recorded · Shanghai, China
Investors in latest funding
Lead: HSG , IDG Capital , Hillhouse Investment , 5Y Capital
Overview
Anew Labs is described by Reuters as ByteDance’s AI drugmaking unit, now Shanghai-headquartered and spun off so drug discovery can run on different industry logic than ByteDance’s core consumer internet business. On September 16, 2026 Kane Wu reported that two people with knowledge of the matter said the company had completed a $290 million inaugural external fundraising at a $1.5 billion valuation. Named leads: HSG, IDG Capital, and Hillhouse Investment, with 5Y Capital as co-lead. Other investors named: Gaorong Ventures, Primavera Venture Partners, Boyu Capital, strategic investor SBP Group, and state-backed Shanghai Future Industries Fund. ByteDance is said to hold 56% after the fundraising. None of those firms have Venture Capital Tracker /fund/ pages. PHYMI’s September seed named IDG as lead — that is a different deal (/startup/phymi). Do not treat HSG as Sequoia Capital. Series letter, ARR, pipeline assets, and whether the $1.5 billion is pre- or post-money were not in the Reuters item. Company silent in that report.
Why Anew Labs is interesting
September 16, 2026 Reuters (two people, not public): Shanghai-headquartered Anew Labs completed a $290 million fundraising after being spun out of ByteDance, at a $1.5 billion valuation. Leads named: HSG (formerly Sequoia China), IDG Capital, Hillhouse Investment, with 5Y Capital as co-lead. ByteDance retains 56% after the raise, per a second source. ByteDance and the investors did not immediately respond to Reuters. This is reported, not company-disclosed. HSG is not Sequoia Capital’s US /fund/sequoia page.
Product & use cases
Reuters: AI for drug discovery. No product metrics, named assets, or clinical-stage claims in that report.
- AI-assisted drug discovery (as described by Reuters sources)
Key facts
- Sep 16, 2026 Reuters: $290M at $1.5B — two people; company silent
- HSG, IDG Capital, Hillhouse led; 5Y Capital co-lead (sources)
- ByteDance 56% after the raise (second source)
- HSG ≠ Sequoia Capital US
Funding history (newest first)
Inaugural external (reported)
2026-09 $290M Valuation: $1.5B- HSG (lead)
- IDG Capital (lead)
- Hillhouse Investment (lead)
- 5Y Capital (lead)
Competitive landscape
Edge: A $1.5 billion mark on a ByteDance spinout whose only public print is an anonymous Reuters item. The diligence object is confirmation, not a cap table we can see.
Do not analogize to a US Series B biotech round. This is a reported inaugural external raise inside a ByteDance-controlled vehicle.
-
ByteDance incumbent
Parent/spinout source. Retains 56% after the reported raise, per Reuters.
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Anew Labs's financing or category context.
FAQs about Anew Labs
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.